Table 1.
Baseline characteristics by quintile of baseline NT-proBNP level (N = 3664)
| Characteristic | Overall | ≤37.1 | 37.14–92.5 | 92.71–199.2 | 199.21–497 | >497 |
|---|---|---|---|---|---|---|
| Patients, n | 3664 | 733 | 733 | 732 | 733 | 733 |
| Age, yr | 57.8 (11.0) | 53.4 (11.6) | 56.6 (10.8) | 58.9 (10.7) | 59.6 (10.5) | 60.4 (9.9) |
| Women, n | 1673 (46) | 269 (37) | 350 (48) | 349 (48) | 390 (53) | 315 (43) |
| Race/ethnicity | ||||||
| Non-Hispanic white | 1544 (42) | 317 (43) | 311 (42) | 347 (47) | 318 (43) | 251 (34) |
| Non-Hispanic black | 1505 (41) | 332 (45) | 312 (43) | 268 (37) | 284 (39) | 309 (42) |
| Hispanic | 467 (13) | 50 (7) | 71 (10) | 92 (13) | 109 (15) | 145 (20) |
| Other | 148 (4) | 34 (5) | 39 (5) | 25 (3) | 22 (3) | 28 (4) |
| Estimated glomerular filtration rate, ml/min per 1.73 m2 | 44.3 (14.8) | 53.6 (14.2) | 48.0 (14.5) | 43.3 (13.8) | 40.0 (12.4) | 36.3 (12.3) |
| Urinary protein to creatinine ratio from 24-h urine test | 0.2 (0.1–0.8) | 0.1 (0.0–0.2) | 0.1 (0.0–0.5) | 0.1 (0.1–0.5) | 0.2 (0.1–1.1) | 0.6 (0.1–2.6) |
| Diabetes mellitus | 1785 (49) | 244 (33) | 312 (43) | 353 (48) | 402 (55) | 474 (65) |
| History of CVD | 1207 (33) | 100 (14) | 151 (21) | 210 (29) | 303 (41) | 443 (60) |
| History of atrial fibrillation | 609 (17) | 60 (8) | 82 (11) | 99 (14) | 147 (20) | 221 (30) |
| History of CHF | 348 (9) | 17 (2) | 22 (3) | 34 (5) | 90 (12) | 185 (25) |
| Current smoker | 464 (13) | 68 (9) | 74 (10) | 92 (13) | 113 (15) | 117 (16) |
| Alcohol use | 2312 (63) | 540 (74) | 510 (70) | 455 (62) | 419 (57) | 388 (53) |
| Body mass index, kg/m2 | 32.1 (7.9) | 31.9 (6.8) | 32.1 (7.7) | 32.4 (8.5) | 32.3 (8.3) | 31.9 (7.9) |
| Systolic blood pressure, mm Hg | 128.6 (22.1) | 119.3 (15.9) | 123.9 (18.6) | 126.0 (19.2) | 132.9 (22.4) | 141.1 (26.3) |
| Diastolic blood pressure, mm Hg | 71.5 (12.8) | 72.5 (11.2) | 71.9 (11.6) | 70.3 (12.1) | 71.0 (13.5) | 71.8 (15.3) |
| Hemoglobin, g/dl | 12.6 (1.8) | 13.5 (1.6) | 12.8 (1.6) | 12.6 (1.6) | 12.2 (1.7) | 11.8 (1.9) |
| LDL cholesterol, mg/dl | 103.0 (35.3) | 107.2 (33.5) | 104.7 (35.2) | 102.5 (35.0) | 101.5 (34.1) | 99.1 (38.2) |
| HDL cholesterol, mg/dl | 47.7 (15.5) | 47.3 (14.3) | 48.5 (15.7) | 48.0 (15.3) | 48.1 (16.4) | 46.5 (15.8) |
| ACEi/ARBs | 2509 (68) | 486 (66) | 509 (69) | 508 (69) | 514 (70) | 492 (67) |
| Diuretics | 2164 (59) | 327 (45) | 387 (53) | 441 (60) | 449 (61) | 560 (76) |
| β-Blockers | 1795 (49) | 181 (25) | 269 (37) | 360 (49) | 450 (61) | 535 (73) |
| Fibroblast growth factor−23 (RU/ml), median (IQR) | 145.0 (96.5–235.7) | 102.5 (75.7–149.7) | 124.3 (87.1–188.1) | 142.6 (97.4–218.1) | 169.8 (115.9–258.8) | 221.8 (142.1–361.6) |
| Serum phosphorus, mg/dl | 3.7 (0.7) | 3.5 (0.6) | 3.6 (0.6) | 3.7 (0.7) | 3.8 (0.7) | 3.9 (0.7) |
| Total parathyroid hormone, pg/ml, median (IQR) | 54.0 (35.0–89.0) | 41.2 (30.0–58.0) | 47.8 (32.6–78.0) | 53.7 (33.0–84.0) | 62.0 (39.0–101.2) | 80.0 (49.5–128.1) |
ACEi, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; CHF, congestive heart failure; CVD, cardiovascular disease; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Entries are mean (SD) or n (%), except as noted. All plasma concentrations are in nanograms per liter (ng/l).